PIK3CA and non-small cell lung carcinoma: To investigate the impact of PI3K mutations on bone metastasis of NSCLC and primary immune checkpoint resistance, we utilized the CRISPR/Cas9 editing system to, respectively, construct PIK3CA-E545K heterozygous and homozygous knock-in mutants in A549 or H1703 cells (Fig. 2A).